Profile data is unavailable for this security.
About the company
ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. It is also focused on development and commercialization of the ARR-002 program.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2021
- Employees40.00
- LocationArrivent Biopharma Inc18 Campus Blvd., Suite 100NEWTOWN SQUARE 19073-3269United StatesUSA
- Phone+1 (240) 780-6356
- Fax+1 (302) 636-5454
- Websitehttps://arrivent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| iTeos Therapeutics Inc | 0.00 | -135.31m | 643.78m | 157.00 | -- | 1.19 | -- | -- | -3.78 | -3.78 | 0.00 | 15.10 | 0.00 | -- | -- | 0.00 | -19.93 | 5.84 | -20.88 | 7.02 | -- | -- | -- | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Exscientia PLC (ADR) | 25.43m | -184.88m | 646.99m | 483.00 | -- | 1.43 | -- | 25.44 | -1.47 | -1.47 | 0.2023 | 3.58 | 0.0346 | 1,096.08 | 9.86 | 52,654.05 | -25.16 | -- | -29.09 | -- | -36.47 | -- | -726.94 | -- | 6.22 | -- | 0.0505 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 652.10m | 121.00 | -- | 2.50 | -- | 13.04 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Savara Inc | 0.00 | -64.49m | 652.19m | 37.00 | -- | 5.35 | -- | -- | -0.3848 | -0.3848 | 0.00 | 0.8819 | 0.00 | -- | -- | 0.00 | -44.84 | -36.86 | -47.26 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1782 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Mineralys Therapeutics Inc | 0.00 | -90.80m | 652.88m | 28.00 | -- | 1.99 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 657.51m | 100.00 | -- | 1.82 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| GH Research PLC | 0.00 | -35.59m | 662.32m | 49.00 | -- | 3.02 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Zymeworks Inc | 50.46m | -125.97m | 663.21m | 275.00 | -- | 1.53 | -- | 13.14 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 665.06m | 285.00 | -- | 1.57 | -- | 287.78 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Castle Biosciences Inc | 250.73m | -30.80m | 668.65m | 610.00 | -- | 1.66 | -- | 2.67 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Arrivent Biopharma Inc | -100.00bn | -100.00bn | 674.90m | 40.00 | -- | 2.12 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| SNDL Inc | 664.05m | -100.22m | 690.30m | 2.52k | -- | 0.7776 | -- | 1.04 | -0.3828 | -0.3917 | 2.54 | 3.41 | 0.5855 | 4.67 | 33.35 | 263,931.10 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| AnaptysBio Inc | 22.96m | -163.30m | 695.81m | 117.00 | -- | 14.56 | -- | 30.30 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 708.73m | 224.00 | -- | 1.17 | -- | 10,422.52 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Data as of May 16 2024. Currency figures normalised to Arrivent Biopharma Inc's reporting currency: US Dollar USD
24.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HHLR Advisors Ltd.as of 30 Jan 2024 | 4.48m | 14.03% |
| Octagon Capital Advisors LPas of 26 Jan 2024 | 1.74m | 5.46% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 634.76k | 1.99% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 606.74k | 1.90% |
| Alphacentric Advisors LLCas of 31 Mar 2024 | 83.00k | 0.26% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 77.76k | 0.24% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 27.16k | 0.09% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 19.25k | 0.06% |
| The Bank of New York Mellon Corp. (Investment Management)as of 31 Mar 2024 | 18.00k | 0.06% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 9.77k | 0.03% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
